All In Biotech

Drug Trial Radar · NCT00792740

Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

51

Actual

Start

Oct 22, 2007

Primary completion

Dec 2008

Study completion Mar 11, 2009

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
First posted
Nov 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objectives: The primary objective of the study was to determine the ability of ITF2357, administered orally at the dose of 50 mg b.i.d. for 8 consecutive weeks, to induce complete healing of mucosal ulcerations of ileum and/or colon, assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies. The secondary objectives of the study were: * to evaluate the effect of ITF2357 on endoscopic disease activity assessed using both the Crohn's Disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score of Crohn's Disease (SES-CD); * to evaluate the effect of ITF2357 on clinical disease activity, assessed using the Crohn's Disease Activity Index (CDAI); * to assess the safety and tolerability of ITF2357; to assess the pharmacokinetic profile of ITF2357.

Conditions

  • Crohn's Disease

Interventions

  • ITF2357Drug

    ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.

  • PlaceboOther

    Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or ColonTime frame: At week 8

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • AZ Sint Lucas Gastro-enterologie

    Assebroek, Belgium

  • Imelda Hospital Gastro-enterology dept.

    Bonheiden, Belgium

  • CHU Saint-Pierre Médecine Interne

    Brussels, Belgium

  • UZ Gent Gastro-enterologie 1K12IE

    Ghent, Belgium

  • AZ Groeninge (St-Niklaas) Gastro-enterologie

    Kortrijk, Belgium

  • University Hospital Gasthuisber

    Leuven, Belgium

  • Divisione di Gatroenterologia Istituto Clinico Humanitas IRCCS in. Gastroenterology

    Rozzano, Italy

  • Vrije Universiteit (VU) Medisch Centrum Afdeling M.D.L.ziekten

    Amsterdam, Netherlands

  • Academisch Medisch Centrum (AMC) Afdeling M.D.L. ziekten

    Amsterdam, Netherlands

  • Leids Universitair Medisch Centrum (LUMC) Afdeling M.D.L. ziekten

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.